Short Interest in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Declines By 21.3%

Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 1,180,000 shares, a decrease of 21.3% from the November 30th total of 1,500,000 shares. Based on an average daily trading volume, of 16,290,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.5% of the shares of the company are short sold.

Tevogen Bio Stock Down 1.9 %

Shares of TVGN traded down $0.02 during trading hours on Friday, reaching $1.03. 1,186,045 shares of the stock traded hands, compared to its average volume of 4,671,929. The company's 50-day moving average price is $1.49 and its two-hundred day moving average price is $0.93. Tevogen Bio has a 52-week low of $0.26 and a 52-week high of $21.09.

Insider Activity

In other Tevogen Bio news, insider Neal Flomenberg sold 1,078,600 shares of the company's stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $1.62, for a total value of $1,747,332.00. Following the completion of the transaction, the insider now directly owns 4,254,302 shares in the company, valued at $6,891,969.24. This represents a 20.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 56.60% of the company's stock.

Hedge Funds Weigh In On Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. HGC Investment Management Inc. bought a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 223,077 shares of the company's stock, valued at approximately $82,000. HGC Investment Management Inc. owned 0.13% of Tevogen Bio at the end of the most recent quarter.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.